PFE's robust late-stage pipeline, recent FDA wins and deep oncology bets position it for long-term growth through 2030.

AstraZeneca chief executive Pascal Soriot is considering moving the company's stock exchange listing from the UK to the US – ...

The Contrast Media Market is projected to grow at a CAGR of 5-6%. Key factors influencing the contrast media market include ...

A potential $4 billion licensing deal with Vor Bio triggered a slide in RemeGen's stock price. Otsuka obtained a BCMAXCD3 ...

Joshua K. Sabari, MD, of NYU Langone Health discusses promising results for zongertinib in HER2-mutant NSCLC; the tyrosine ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

Thousands of women battling advanced breast cancer could be denied access to crucial life-extending medication due to an ...

One of the most read (and recommended) books on investing is Benjamin Graham’s The Intelligent Investor. Among many others, ...

A mum who has breast cancer is one of thousands of women who could be "missing out" on life-extending drugs because of the way they are assessed by the health service, a charity has warned. Breast ...

Bangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation ...